Summary of findings 5. Scheduled PDE5I compared to scheduled intraurethral prostaglandin E1 for post‐prostatectomy erectile dysfunction (short term).
| Scheduled PDE5I compared to scheduled intraurethral prostaglandin E1 for post‐prostatectomy erectile dysfunction (short term) | |||||
| Patient or population: post‐prostatectomy erectile dysfunction (short term) Setting: outpatient clinic Intervention: scheduled PDE5I Comparison: scheduled intraurethral prostaglandin E1 | |||||
| Outcomes | № of participants (studies) Follow up | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects* (95% CI) | |
| Risk with scheduled intraurethral prostaglandin E1 | Risk difference with scheduled PDE5I | ||||
| Self‐reported potency assessed with: Intercourse success rate follow up: mean 11 months | 156 (1 RCT) | ⊕⊝⊝⊝ VERY LOW 1 2 | RR 1.10 (0.79 to 1.52) | Study population | |
| 464 per 1,000 | 46 more per 1,000 (97 fewer to 241 more) | ||||
| Erectile function assessed with: International Index of Erectile Function‐Erectile Function domain > 26 follow up: mean 11 months | 156 (1 RCT) | ⊕⊝⊝⊝ VERY LOW 1 2 | RR 1.64 (0.84 to 3.20) | Study population | |
| 144 per 1,000 | 92 more per 1,000 (23 fewer to 318 more) | ||||
| Erectile function assessed with: International Index of Erectile Function‐Erectile Function domain > 17 follow up: mean 11 months | 156 (1 RCT) | ⊕⊝⊝⊝ VERY LOW 1 2 | RR 1.20 (0.79 to 1.81) | Study population | |
| 340 per 1,000 | 68 more per 1,000 (71 fewer to 276 more) | ||||
| Serious adverse events ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ |
| Sexual quality of life ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ |
| Treatment discontinuation ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ |
| International Index of Erectile Function ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; | |||||
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | |||||
1 Downgraded by one level for study limitations: unclear or high risk of bias in almost all domains.
2 Downgraded by two levels for imprecision: wide confidence interval crosses assumed threshold of clinically important difference.